Exelixis (EXEL) Income from Continuing Operations (2010 - 2026)
Exelixis (EXEL) posted quarterly Income from Continuing Operations of 210467000.0 for Q2 2026, up 31.86% year-over-year from 159616000.0 in Q2 2025, and down 13.93% quarter-over-quarter from 244528000.0 in Q1 2026.
Exelixis (EXEL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Exelixis' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 210467000.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 31.86% year-over-year to 210467000.0; the TTM figure through Apr 2026 stood at 833421000.0 (up 29.5% YoY), while the FY2026 annual figure was 782570000.0, up 50.13% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 210467000.0, down from 244528000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 244528000.0 in Q1 2026, with the low at 30173000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 85518000.0 (2023), against an average of 112020647.06.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 131.71% in 2022, then soared 11232.66% in 2024.
- Exelixis' Income from Continuing Operations stood at 30173000.0 in 2022, then jumped by 383.43% to 85518000.0 in 2023, then soared by 37.95% to 117973000.0 in 2024, then soared by 64.09% to 193578000.0 in 2025, then grew by 8.72% to 210467000.0 in 2026.
- Business Quant data shows EXEL's Income from Continuing Operations at 210467000.0 in Q2 2026, 244528000.0 in Q1 2026, and 193578000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 212.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 212.05 Mn |
| Apr 3, 2026 | 210.47 Mn |
| Jan 2, 2026 | 244.53 Mn |
| Oct 3, 2025 | 193.58 Mn |
| Jul 4, 2025 | 184.85 Mn |
| Apr 4, 2025 | 159.62 Mn |
| Jan 3, 2025 | 139.86 Mn |
| Sep 27, 2024 | 117.97 Mn |
| Jun 28, 2024 | 226.12 Mn |
| Mar 29, 2024 | 37.32 Mn |
| Dec 29, 2023 | 85.52 Mn |
| Sep 29, 2023 | 1.04 Mn |
| Jun 30, 2023 | 81.18 Mn |
| Mar 31, 2023 | 40.03 Mn |
| Dec 30, 2022 | -30.17 Mn |
| Sep 30, 2022 | 73.21 Mn |
| Jul 1, 2022 | 70.67 Mn |
| Apr 1, 2022 | 68.57 Mn |
| Dec 31, 2021 | 95.17 Mn |
| Oct 1, 2021 | 38.20 Mn |